Published in PLoS Negl Trop Dis on January 26, 2010
Control of neglected tropical diseases. N Engl J Med (2007) 14.49
Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol (1981) 9.21
Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med (2006) 8.63
If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA (1983) 8.36
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
"Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med (2005) 6.33
Probability of adverse events that have not yet occurred: a statistical reminder. BMJ (1995) 5.55
A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol (2006) 3.10
Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol (2006) 2.87
Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development goals. BMJ (2004) 2.78
"Neglected" diseases but unrecognised successes--challenges and opportunities for infectious disease control. Lancet (2004) 2.64
Achieving the Millennium Development Goals. Lancet (2005) 2.50
New initiatives against Africa's worms. Trans R Soc Trop Med Hyg (2005) 1.99
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol (2006) 1.82
Recent progress in integrated neglected tropical disease control. Trends Parasitol (2007) 1.58
Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis (1999) 1.48
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol (2002) 1.48
Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria. Am J Trop Med Hyg (2002) 1.46
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology (2000) 1.42
Conceptualizing integration: a framework for analysis applied to neglected tropical disease control partnerships. PLoS Negl Trop Dis (2008) 1.38
Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study. PLoS Negl Trop Dis (2008) 1.26
Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans R Soc Trop Med Hyg (2005) 1.01
Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf (2008) 0.99
Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis (2009) 0.94
Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg (2007) 0.88
Additional power computations for designing comparative Poisson trials. Am J Epidemiol (1982) 0.83
The possibility of eliminating blinding trachoma. Lancet Infect Dis (2003) 1.47
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med (2007) 1.40
Off-label use of quetiapine in New Zealand--a cause for concern? N Z Med J (2011) 1.39
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol (2008) 1.16
Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol (2002) 1.13
Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol (2008) 1.00
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2002) 0.94
Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol (2010) 0.93
A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. Clin Infect Dis (2012) 0.91
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry (2013) 0.89
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol (2010) 0.89
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord (2009) 0.88
Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg (2007) 0.88
Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disord (2011) 0.87
Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med (2012) 0.87
Anti-anxiety drugs reduce conflict-specific "theta"--a possible human anxiety-specific biomarker. J Affect Disord (2012) 0.86
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res (2002) 0.86
Dose- and exposure-response to ketamine in depression. Biol Psychiatry (2011) 0.85
Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol (2009) 0.85
Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol (2011) 0.84
Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry (2014) 0.84
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol (2006) 0.84
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis. J Affect Disord (2010) 0.84
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol (2009) 0.84
Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet (2002) 0.83
Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat (2012) 0.83
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med (2004) 0.83
Factors associated with hospitalization of adult psychiatric patients: cluster analysis. Australas Psychiatry (2013) 0.82
The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. PLoS Negl Trop Dis (2008) 0.82
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. Eur J Clin Pharmacol (2009) 0.81
Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther (2013) 0.81
Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discov Ther (2014) 0.81
Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. J Clin Pharmacol (2010) 0.81
Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br J Clin Pharmacol (2003) 0.81
The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull (2007) 0.80
The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry (2008) 0.80
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol (2006) 0.80
Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol (2011) 0.80
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract (2011) 0.78
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol (2009) 0.78
Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother (2013) 0.78
'Violence is not part of our job': a thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues Ment Health Nurs (2014) 0.78
Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA Psychiatry (2013) 0.77
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol (2011) 0.77
Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med (2013) 0.76
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res (2009) 0.76
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 0.75
Comparative efficacy of anti-manic drugs in acute mania. Lancet (2012) 0.75
Anterior Cingulate Implant for Alcohol Dependence: Case Report. Neurosurgery (2016) 0.75
Do all antidepressants cause QT prolongation--how good is the evidence? N Z Med J (2013) 0.75
Factors related to postgraduate retention of medical graduates in New Zealand. N Z Med J (2013) 0.75
Risk management and clinical practice. N Z Med J (2015) 0.75
Academic performance and career choices of older medical students at the University of Otago. N Z Med J (2011) 0.75
Postgraduation retention of medical students from Otago and Auckland medical programmes. N Z Med J (2014) 0.75
Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce. J Clin Pharmacol (2005) 0.75